Digital Exclusives
Superutilizers make up 1 percent of the population but use upward of 30 percent of health care resources. Here’s one social model to tackle the problem.
Some Wharton entrepreneurs are doing well and doing good by trying to cure what ails American health care.
Digital health startup Wellthie is taking advantage of insurance trends and consumer demands post-health care reform.
A dose of business principles, in large part from venture philanthropy, is changing the way medical research is done in the U.S. health care industry.
Two alumnae launch into rarefied air with their own female-led venture capital fund for startups healing heath care with digital technology.
Are recent health care mergers a good thing? Who are the winners and losers in these deals? Jeff Voigt finds answers in research on past consolidations.
David Fajgenbaum is battling a little-known, extremely deadly disease as a researcher, a physician, an advocate, an entrepreneur and a patient.
Health Care Management alumni reflect on how and why raising funds for the Kinney Alumni Scholarship was so successful.
As part of the Affordable Care Act, primary care providers got paid more to take Medicaid patients. Did it work to provide better care to more people?
Could health gains from the ACA be in jeopardy from reluctance to continue state-based Medicaid payments? A Wharton Health Care Management alum sounds off.
With upward of 39 million more Americans receiving health care coverage through health care reform, will the system be able to meet the demand?
Wharton alumni are right in the thick of meaty health care issues, like the cost of specialty drugs. Here’s a recap of some notable graduates talking about the topic for SiriusXM.
The Mack Institute hosted its first Innovation Clinic of many to empower thinkers and doers across Penn’s campus.
The health care capabilities of Apple’s ”most personal device ever” could boost a marketplace filled with promising startups, says a medical device specialist.
Health care expert Jeff Voigt looks at a controversial liver drug to illustrate the growing importance of medical cost-effectiveness.
Wharton's own sports medicine pioneer opens up about everything from why he pursued an MBA in his early 50s to how he discovered new treatment options for core muscle injuries.
